OCS-02 (licaminlimab)
Dry Eye Disease (DED)
Key Facts
About Oculis Holding AG
Oculis is dedicated to improving the sight and lives of patients through innovative topical ophthalmic therapies. Its lead asset, OCS-01, is a novel topical formulation of dexamethasone in Phase 3 development for DME and inflammation following cataract surgery, potentially offering a non-invasive alternative to injections. The company's strategy is built on its proprietary SNAP technology platform, which enables efficient drug delivery across ocular barriers, and it has strengthened its position through a Nasdaq IPO and key clinical advancements.
View full company profileAbout Oculis Holding AG
Oculis is dedicated to improving the sight and lives of patients through innovative topical ophthalmic therapies. Its lead asset, OCS-01, is a novel topical formulation of dexamethasone in Phase 3 development for DME and inflammation following cataract surgery, potentially offering a non-invasive alternative to injections. The company's strategy is built on its proprietary SNAP technology platform, which enables efficient drug delivery across ocular barriers, and it has strengthened its position through a Nasdaq IPO and key clinical advancements.
View full company profileTherapeutic Areas
Other Dry Eye Disease (DED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Urcosimod (OK-101) | OKYO Pharma | Preclinical |